NASDAQ
LKFT
Last Price
US $29.98
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Lakefront Biotherapeutics N.V. cash flow to debt ratio of -3.72K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
Lakefront Biotherapeutics N.V. has insufficient data to evaluate this check.
Financial risk - Healthy debt to equity ratio.
Lakefront Biotherapeutics N.V. has insufficient data to evaluate this check.
Financial risk - Healthy debt to equity ratio development.
Lakefront Biotherapeutics N.V. has insufficient data to evaluate this check.
Financial stability - Net debt/EBITDA.
Lakefront Biotherapeutics N.V. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial stability - ICR.
Lakefront Biotherapeutics N.V. earns at least as much interest as it pays. Interest obligations are fully covered.
Financial risk - Profit margin growth.
Lakefront Biotherapeutics N.V. has insufficient data to evaluate this check.
Financial risk - Short term assets vs short term liabilities.
Lakefront Biotherapeutics N.V. has insufficient data to evaluate this check.
Increasing performance - ROA.
Lakefront Biotherapeutics N.V.'s return on assets of 14.49% is higher than the 5.00% threshold, indicating efficient asset utilization
Increasing performance - Absolute return on equity.
Lakefront Biotherapeutics N.V.'s return on equity of 16.88%, is higher than 15.00%, indicating good performance
Decreasing performance - Earnings quality.
Lakefront Biotherapeutics N.V.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Lakefront Biotherapeutics N.V. had positive net income in only 1.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Lakefront Biotherapeutics N.V. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Lakefront Biotherapeutics N.V. has negative free cash flow, indicating cash burn
Decreasing performance - Healthy earnings growth.
Lakefront Biotherapeutics N.V. has insufficient data to evaluate this check.
Decreasing performance - Healthy revenue growth.
Lakefront Biotherapeutics N.V. has insufficient data to evaluate this check.
Increasing performance - ROIC.
ROIC 18.22% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.
Decreasing performance - 3-year revenue CAGR.
Lakefront Biotherapeutics N.V. has insufficient revenue history to calculate 3-year revenue CAGR.
Decreasing performance - Revenue consistency.
Lakefront Biotherapeutics N.V. had revenue growth in only 0.00 out of 5 years, indicating inconsistent revenue performance
Decreasing performance - ROE consistency.
Lakefront Biotherapeutics N.V. had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Lakefront Biotherapeutics N.V. has insufficient data to evaluate this check.
Undervalued - Earnings yield.
Lakefront Biotherapeutics N.V. has an earnings yield of 25.17%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings
Overvalued - EBITDA valuation.
Lakefront Biotherapeutics N.V. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Undervalued - EV/EBITDA.
Lakefront Biotherapeutics N.V. has an EV/EBITDA ratio of 3.46x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Overvalued - PEG ratio value.
Lakefront Biotherapeutics N.V. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
Lakefront Biotherapeutics N.V. has a price-to-book ratio of 0.52x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
Lakefront Biotherapeutics N.V. has a price-to-sales ratio of 1.63x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
16.88%
Return on equity
ROIC: 18.22%
Valuation History
3.5X
Price to Earnings
EV/EBITDA: 3.5X
Cash flow
Profit margin
-
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
Fair Value
Market $29.98
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.